Table 1. Patient Characteristicsa.
| Characteristic | Patient data (Nā=ā101) |
|---|---|
| Age, y | |
| Median (range) | 56 (31-85) |
| <65 | 79 (78.2) |
| ā„65 | 22 (21.8) |
| Stage IV disease at initial diagnosis | 34 (33.7) |
| Hormone receptor status | |
| ER and/or PR positive | 72 (71.3) |
| ER and PR negative | 29 (28.7) |
| Prior lines of therapy, median (range) | |
| Overall | 5 (2-16) |
| Metastatic setting | 4 (2-15) |
| Previous therapies for metastatic breast cancer | |
| Trastuzumab | 100 (99.0) |
| Pertuzumab | 82 (81.2) |
| Ado-trastuzumab-emtansine | 94 (93.1) |
| Lapatinib | 33 (32.7) |
| Trastuzumab-deruxtecan | 101 (100) |
| Duration of trastuzumab-deruxtecan therapy, median (range), mo | 8.9 (1.4-25.8) |
| Reason for trastuzumab-deruxtecan discontinuation | |
| Progression | 82 (81.2) |
| Toxicity | 18 (17.8) |
| Unknown | 1 (1.0) |
| TTC immediately after trastuzumab-deruxtecan | 86 (85.1) |
| Known brain metastases prior to TTC | |
| Yes | 39 (38.6) |
| No | 62 (61.4) |
| Classification of brain metastasesb | |
| Previous local treatment and stable brain metastases prior to TTC | 20 (51.3) |
| Previous local treatment and progressive brain metastases prior to TTC | 15 (38.5) |
| No previous local treatment and stable brain metastases prior to TTC | 3 (7.7) |
| No previous local treatment and progressive brain metastases prior to TTC | 1 (2.6) |
Abbreviations: ER, estrogen receptor; PR, progesterone receptor; TTC, tucatinib combined with trastuzumab and capecitabine.
a
Unless indicated otherwise, data are expressed as No. (%) of patients.
b
Includes the 39 patients with known brain metastases prior to TTC.